newsfilter
← Latest News
GlobeNewswire·

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3